An interventional study of Enterra Therapy System (H9900014) in Severe to Morbid Obesity and Type 2 Diabetes, sponsored by MedtronicNeuro. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-02-05.
Sponsored by MedtronicNeuro · Not applicable, Interventional, and Treatment
The purpose of this study is to test the effect of an implanted device that stimulates the stomach on weight loss in patients suffering from obesity and type 2 diabetes.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 46 is below the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →MedtronicNeuro is the lead sponsor of 69 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Mean excess weight loss and percent excess weight loss
Time frame: 12 months
Diabetes status and use of diabetes medication
Time frame: 12 months
This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MedtronicNeuro